Exosomes as nanocarriers for immunotherapy of cancer and inflammatory diseases

Clinical Immunology

Volumn 160, Issue 1, 2015, Pages 46-58

  Tran, Thanh Huyen ^a   Mattheolabakis, George ^a   Aldawsari, Hibah ^b   Amiji, Mansoor ^a,b  

^a NORTHEASTERN UNIVERSITY   (United States)

^b KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

Autoimmune diseases; Cancer; Exosomes; Immunotherapy; Nanocarrier

Indexed keywords

CANCER VACCINE; IMMUNOLOGIC AGENT; MICRORNA; NANOCARRIER; DRUG CARRIER;

ANTIGEN PRESENTING CELL; BIOLOGICAL FUNCTIONS; CANCER IMMUNOTHERAPY; CYTOLOGY; EXOSOME; EXPERIMENTAL AUTOIMMUNE DISEASE; GENE DELIVERY SYSTEM; HUMAN; IMMUNOMODULATION; INFLAMMATORY BOWEL DISEASE; INFLAMMATORY DISEASE; MULTIPLE SCLEROSIS; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; AUTOIMMUNE DISEASES; IMMUNOLOGY; IMMUNOTHERAPY; INFLAMMATION; NEOPLASMS; PROCEDURES;

ANTIGEN-PRESENTING CELLS; AUTOIMMUNE DISEASES; DRUG CARRIERS; EXOSOMES; HUMANS; IMMUNOTHERAPY; INFLAMMATION; NEOPLASMS;

EID: 84940462854     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2015.03.021     Document Type: Review

References (107)

1. Stewart B.W., Wild C.P. World Cancer Report 2014, IARC Scientific Publisher.
2. Chatenoud L. Immune therapies of autoimmune diseases: are we approaching a real cure?. Curr. Opin. Immunol. 2006, 18:710-717.
3. Cohen I.R. Activation of benign autoimmunity as both tumor and autoimmune disease immunotherapy: A comprehensive review. J. Autoimmun. 2014, 54C:112-117.
4. Scott A.M., Wolchok J.D., Old L.J. Antibody therapy of cancer. Nat. Rev. Cancer 2012, 12:278-287.
5. Caspi R.R. Immunotherapy of autoimmunity and cancer: the penalty for success. Nat. Rev. Immunol. 2008, 8:970-976.
6. Paulis L.E., Mandal S., Kreutz M., Figdor C.G. Dendritic cell-based nanovaccines for cancer immunotherapy. Curr. Opin. Immunol. 2013, 25:389-395.
7. Klippstein R., Pozo D. Nanotechnology-based manipulation of dendritic cells for enhanced immunotherapy strategies. Nanomedicine 2010, 6:523-529.
8. Mellman I., Coukos G., Dranoff G. Cancer immunotherapy comes of age. Nature 2011, 480:480-489.
9. Vanneman M., Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat. Rev. Cancer 2012, 12:237-251.
10. Tran T.H., Amiji M.M. Targeted delivery systems for biological therapies of inflammatory diseases. Expert Opin. Drug Deliv. 2015, 12:393-414.
11. Amoozgar Z., Goldberg M.S. Targeting myeloid cells using nanoparticles to improve cancer immunotherapy. Adv. Drug Deliv. Rev. 2014, (in press).
12. Natasha G., Gundogan B., Tan A., Farhatnia Y., Wu W., Rajadas J., Seifalian A.M. Exosomes as immunotheranostic nanoparticles. Clin. Ther. 2014, 36:820-829.
13. Hamdy S., Haddadi A., Hung R.W., Lavasanifar A. Targeting dendritic cells with nano-particulate PLGA cancer vaccine formulations. Adv. Drug Deliv. Rev. 2011, 63:943-955.
14. Thery C., Zitvogel L., Amigorena S. Exosomes: composition, biogenesis and function. Nat. Rev. Immunol. 2002, 2:569-579.
15. Johnsen K.B., Gudbergsson J.M., Skov M.N., Pilgaard L., Moos T., Duroux M. A comprehensive overview of exosomes as drug delivery vehicles - endogenous nanocarriers for targeted cancer therapy. Biochim. Biophys. Acta 2014, 1846:75-87.
16. Kim S.H., Lechman E.R., Bianco N., Menon R., Keravala A., Nash J., Mi Z., Watkins S.C., Gambotto A., Robbins P.D. Exosomes derived from IL-10-treated dendritic cells can suppress inflammation and collagen-induced arthritis. J. Immunol. 2005, 174:6440-6448.
17. Yang C., Robbins P.D. Immunosuppressive exosomes: a new approach for treating arthritis. Int. J. Rheumatol. 2012, 2012:573528.
18. Futter C.E., White I.J. Annexins and endocytosis. Traffic 2007, 8:951-958.
19. Gastpar R., Gehrmann M., Bausero M.A., Asea A., Gross C., Schroeder J.A., Multhoff G. Heat shock protein 70 surface-positive tumor exosomes stimulate migratory and cytolytic activity of natural killer cells. Cancer Res. 2005, 65:5238-5247.
20. Viaud S., Thery C., Ploix S., Tursz T., Lapierre V., Lantz O., Zitvogel L., Chaput N. Dendritic cell-derived exosomes for cancer immunotherapy: what's next?. Cancer Res. 2010, 70:1281-1285.
21. Blanchard N., Lankar D., Faure F., Regnault A., Dumont C., Raposo G., Hivroz C. TCR activation of human T cells induces the production of exosomes bearing the TCR/CD3/zeta complex. J. Immunol. 2002, 168:3235-3241.
22. Peng P., Yan Y., Keng S. Exosomes in the ascites of ovarian cancer patients: origin and effects on anti-tumor immunity. Oncol. Rep. 2011, 25:749-762.
23. Valadi H., Ekstrom K., Bossios A., Sjostrand M., Lee J.J., Lotvall J.O. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol. 2007, 9:654-659.
24. Laulagnier K., Motta C., Hamdi S., Roy S., Fauvelle F., Pageaux J.F., Kobayashi T., Salles J.P., Perret B., Bonnerot C., Record M. Mast cell- and dendritic cell-derived exosomes display a specific lipid composition and an unusual membrane organization. Biochem. J. 2004, 380:161-171.
25. Vlassov A.V., Magdaleno S., Setterquist R., Conrad R. Exosomes: current knowledge of their composition, biological functions, and diagnostic and therapeutic potentials. Biochim. Biophys. Acta 2012, 1820:940-948.
26. Cheruvanky A., Zhou H., Pisitkun T., Kopp J.B., Knepper M.A., Yuen P.S., Star R.A. Rapid isolation of urinary exosomal biomarkers using a nanomembrane ultrafiltration concentrator. Am. J. Physiol. Renal Physiol. 2007, 292:F1657-F1661.
27. Taylor D.D., Zacharias W., Gercel-Taylor C. Exosome isolation for proteomic analyses and RNA profiling. Methods Mol. Biol. 2011, 728:235-246.
28. Lai R.C., Yeo R.W., Tan K.H., Lim S.K. Exosomes for drug delivery - a novel application for the mesenchymal stem cell. Biotechnol. Adv. 2013, 31:543-551.
29. Chalmin F., Ladoire S., Mignot G., Vincent J., Bruchard M., Remy-Martin J.P., Boireau W., Rouleau A., Simon B., Lanneau D., De Thonel A., Multhoff G., Hamman A., Martin F., Chauffert B., Solary E., Zitvogel L., Garrido C., Ryffel B., Borg C., Apetoh L., Rebe C., Ghiringhelli F. Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J. Clin. Invest. 2010, 120:457-471.
30. Sun D., Zhuang X., Zhang S., Deng Z.B., Grizzle W., Miller D., Zhang H.G. Exosomes are endogenous nanoparticles that can deliver biological information between cells. Adv. Drug Deliv. Rev. 2013, 65:342-347.
31. Thery C., Ostrowski M., Segura E. Membrane vesicles as conveyors of immune responses. Nat. Rev. Immunol. 2009, 9:581-593.
32. Beninson L.A., Fleshner M. Exosomes: an emerging factor in stress-induced immunomodulation. Semin. Immunol. 2014, 26:394-401.
33. Zitvogel L., Regnault A., Lozier A., Wolfers J., Flament C., Tenza D., Ricciardi-Castagnoli P., Raposo G., Amigorena S. Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat. Med. 1998, 4:594-600.
34. Wolfers J., Lozier A., Raposo G., Regnault A., Thery C., Masurier C., Flament C., Pouzieux S., Faure F., Tursz T., Angevin E., Amigorena S., Zitvogel L. Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat. Med. 2001, 7:297-303.
35. Ristorcelli E., Beraud E., Verrando P., Villard C., Lafitte D., Sbarra V., Lombardo D., Verine A. Human tumor nanoparticles induce apoptosis of pancreatic cancer cells. FASEB J. 2008, 22:3358-3369.
36. Chow A., Zhou W., Liu L., Fong M.Y., Champer J., Van Haute D., Chin A.R., Ren X., Gugiu B.G., Meng Z., Huang W., Ngo V., Kortylewski M., Wang S.E. Macrophage immunomodulation by breast cancer-derived exosomes requires Toll-like receptor 2-mediated activation of NF-kappaB. Sci. Rep. 2014, 4:5750.
37. Shevach E.M. Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity 2009, 30:636-645.
38. Okoye I.S., Coomes S.M., Pelly V.S., Czieso S., Papayannopoulos V., Tolmachova T., Seabra M.C., Wilson M.S. MicroRNA-containing T-regulatory-cell-derived exosomes suppress pathogenic T helper 1 cells. Immunity 2014, 41:89-103.
39. Kim S.H., Bianco N.R., Shufesky W.J., Morelli A.E., Robbins P.D. Effective treatment of inflammatory disease models with exosomes derived from dendritic cells genetically modified to express IL-4. J. Immunol. 2007, 179:2242-2249.
40. Zhang H.G., Grizzle W.E. Exosomes and cancer: a newly described pathway of immune suppression. Clin. Cancer Res. 2011, 17:959-964.
41. Peinado H., Aleckovic M., Lavotshkin S., Matei I., Costa-Silva B., Moreno-Bueno G., Hergueta-Redondo M., Williams C., Garcia-Santos G., Ghajar C., Nitadori-Hoshino A., Hoffman C., Badal K., Garcia B.A., Callahan M.K., Yuan J., Martins V.R., Skog J., Kaplan R.N., Brady M.S., Wolchok J.D., Chapman P.B., Kang Y., Bromberg J., Lyden D. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat. Med. 2012, 18:883-891.
42. Wieckowski E.U., Visus C., Szajnik M., Szczepanski M.J., Storkus W.J., Whiteside T.L. Tumor-derived microvesicles promote regulatory T cell expansion and induce apoptosis in tumor-reactive activated CD8+ T lymphocytes. J. Immunol. 2009, 183:3720-3730.
43. Wada J., Onishi H., Suzuki H., Yamasaki A., Nagai S., Morisaki T., Katano M. Surface-bound TGF-beta1 on effusion-derived exosomes participates in maintenance of number and suppressive function of regulatory T-cells in malignant effusions. Anticancer Res. 2010, 30:3747-3757.
44. Liu C., Yu S., Zinn K., Wang J., Zhang L., Jia Y., Kappes J.C., Barnes S., Kimberly R.P., Grizzle W.E., Zhang H.G. Murine mammary carcinoma exosomes promote tumor growth by suppression of NK cell function. J. Immunol. 2006, 176:1375-1385.
45. Yu S., Liu C., Su K., Wang J., Liu Y., Zhang L., Li C., Cong Y., Kimberly R., Grizzle W.E., Falkson C., Zhang H.G. Tumor exosomes inhibit differentiation of bone marrow dendritic cells. J. Immunol. 2007, 178:6867-6875.
46. Zhou M., Chen J., Zhou L., Chen W., Ding G., Cao L. Pancreatic cancer derived exosomes regulate the expression of TLR4 in dendritic cells via miR-203. Cell. Immunol. 2014, 292:65-69.
47. Fang J., Nakamura H., Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv. Drug Deliv. Rev. 2011, 63:136-151.
48. van den Boorn J.G., Schlee M., Coch C., Hartmann G. SiRNA delivery with exosome nanoparticles. Nat. Biotechnol. 2011, 29:325-326.
49. Clayton A., Harris C.L., Court J., Mason M.D., Morgan B.P. Antigen-presenting cell exosomes are protected from complement-mediated lysis by expression of CD55 and CD59. Eur. J. Immunol. 2003, 33:522-531.
50. Quah B.J., O'Neill H.C. The immunogenicity of dendritic cell-derived exosomes. Blood Cells Mol. Dis. 2005, 35:94-110.
51. Zhuang X., Xiang X., Grizzle W., Sun D., Zhang S., Axtell R.C., Ju S., Mu J., Zhang L., Steinman L., Miller D., Zhang H.G. Treatment of brain inflammatory diseases by delivering exosome encapsulated anti-inflammatory drugs from the nasal region to the brain. Mol. Ther. 2011, 19:1769-1779.
52. Andre F., Chaput N., Schartz N.E., Flament C., Aubert N., Bernard J., Lemonnier F., Raposo G., Escudier B., Hsu D.H., Tursz T., Amigorena S., Angevin E., Zitvogel L. Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells. J. Immunol. 2004, 172:2126-2136.
53. El Andaloussi S., Lakhal S., Mager I., Wood M.J. Exosomes for targeted siRNA delivery across biological barriers. Adv. Drug Deliv. Rev. 2013, 65:391-397.
54. Record M., Subra C., Silvente-Poirot S., Poirot M. Exosomes as intercellular signalosomes and pharmacological effectors. Biochem. Pharmacol. 2011, 81:1171-1182.
55. Alvarez-Erviti L., Seow Y., Yin H., Betts C., Lakhal S., Wood M.J. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat. Biotechnol. 2011, 29:341-345.
56. Salido-Guadarrama I., Romero-Cordoba S., Peralta-Zaragoza O., Hidalgo-Miranda A., Rodriguez-Dorantes M. MicroRNAs transported by exosomes in body fluids as mediators of intercellular communication in cancer. Onco Targets Ther. 2014, 7:1327-1338.
57. Admyre C., Grunewald J., Thyberg J., Gripenback S., Tornling G., Eklund A., Scheynius A., Gabrielsson S. Exosomes with major histocompatibility complex class II and co-stimulatory molecules are present in human BAL fluid. Eur. Respir. J. 2003, 22:578-583.
58. Mahaweni N.M., Kaijen-Lambers M.E., Dekkers J., Aerts J.G., Hegmans J.P. Tumour-derived exosomes as antigen delivery carriers in dendritic cell-based immunotherapy for malignant mesothelioma. J. Extracell Vesicles 2013, 2.
59. Chaudhuri A.A., So A.Y., Sinha N., Gibson W.S., Taganov K.D., O'Connell R.M., Baltimore D. MicroRNA-125b potentiates macrophage activation. J. Immunol. 2011, 187:5062-5068.
60. Gross J.C., Chaudhary V., Bartscherer K., Boutros M. Active Wnt proteins are secreted on exosomes. Nat. Cell Biol. 2012, 14:1036-1045.
61. Afreen S., Dermime S. The immunoinhibitory B7-H1 molecule as a potential target in cancer: killing many birds with one stone. Hematol. Oncol. Stem Cell Ther. 2014, 7:1-17.
62. Grivennikov S.I., Greten F.R., Karin M. Immunity, inflammation, and cancer. Cell 2010, 140:883-899.
63. Ludwig A.K., Giebel B. Exosomes: small vesicles participating in intercellular communication. Int. J. Biochem. Cell Biol. 2012, 44:11-15.
64. Chaput N., Schartz N.E., Andre F., Taieb J., Novault S., Bonnaventure P., Aubert N., Bernard J., Lemonnier F., Merad M., Adema G., Adams M., Ferrantini M., Carpentier A.F., Escudier B., Tursz T., Angevin E., Zitvogel L. Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection. J. Immunol. 2004, 172:2137-2146.
65. Fujii S., Takayama T., Asakura M., Aki K., Fujimoto K., Shimizu K. Dendritic cell-based cancer immunotherapies. Arch. Immunol. Ther. Exp. (Warsz) 2009, 57:189-198.
66. Matsue H., Morita A., Matsue K., Takashima A. New technologies toward dendritic cell-based cancer immunotherapies. J. Dermatol. 1999, 26:757-763.
67. Gregory A.E., Titball R., Williamson D. Vaccine delivery using nanoparticles. Front. Cell. Infect. Microbiol. 2013, 3:13.
68. Scheerlinck J.P., Greenwood D.L. Virus-sized vaccine delivery systems. Drug Discov. Today 2008, 13:882-887.
69. Amigorena S. Anti-tumour immunotherapy using dendritic-cell-derived exosomes. Res. Immunol. 1998, 149:661-662.
70. O'Loughlin A.J., Woffindale C.A., Wood M.J. Exosomes and the emerging field of exosome-based gene therapy. Curr. Gene Ther. 2012, 12:262-274.
71. Shtam T.A., Kovalev R.A., Varfolomeeva E.Y., Makarov E.M., Kil Y.V., Filatov M.V. Exosomes are natural carriers of exogenous siRNA to human cells in vitro. Cell Commun. Signal 2013, 11:88.
72. Rabinowits G., Gercel-Taylor C., Day J.M., Taylor D.D., Kloecker G.H. Exosomal microRNA: a diagnostic marker for lung cancer. Clin. Lung Cancer 2009, 10:42-46.
73. Xiang X., Poliakov A., Liu C., Liu Y., Deng Z.B., Wang J., Cheng Z., Shah S.V., Wang G.J., Zhang L., Grizzle W.E., Mobley J., Zhang H.G. Induction of myeloid-derived suppressor cells by tumor exosomes. Int. J. Cancer 2009, 124:2621-2633.
74. Peinado H., Aleckovic M., Lavotshkin S., Matei I., Costa-Silva B., Moreno-Bueno G., Hergueta-Redondo M., Williams C., Garcia-Santos G., Ghajar C., Nitadori-Hoshino A., Hoffman C., Badal K., Garcia B.A., Callahan M.K., Yuan J., Martins V.R., Skog J., Kaplan R.N., Brady M.S., Wolchok J.D., Chapman P.B., Kang Y., Bromberg J., Lyden D. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat. Med. 2012, 18:883-891.
75. Momen-Heravi F., Bala S., Bukong T., Szabo G. Exosome-mediated delivery of functionally active miRNA-155 inhibitor to macrophages. Nanomedicine 2014, 10:1517-1527.
76. Cai X., Yin Y., Li N., Zhu D., Zhang J., Zhang C.Y., Zen K. Re-polarization of tumor-associated macrophages to pro-inflammatory M1 macrophages by microRNA-155. J. Mol. Cell Biol. 2012, 4:341-343.
77. Huffaker T.B., Hu R., Runtsch M.C., Bake E., Chen X., Zhao J., Round J.L., Baltimore D., O'Connell R.M. Epistasis between microRNAs 155 and 146a during T cell-mediated antitumor immunity. Cell Rep. 2012, 2:1697-1709.
78. Guo F., Chang C.K., Fan H.H., Nie X.X., Ren Y.N., Liu Y.Y., Zhao L.H. Anti-tumour effects of exosomes in combination with cyclophosphamide and polyinosinic - polycytidylic acid. J. Int. Med. Res. 2008, 36:1342-1353.
79. Utsugi-Kobukai S., Fujimaki H., Hotta C., Nakazawa M., Minami M. MHC class I-mediated exogenous antigen presentation by exosomes secreted from immature and mature bone marrow derived dendritic cells. Immunol. Lett. 2003, 89:125-131.
80. Andre F., Chaput N., Schartz N.E., Flament C., Aubert N., Bernard J., Lemonnier F., Raposo G., Escudier B., Hsu D.H., Tursz T., Amigorena S., Angevin E., Zitvogel L. Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells. J. Immunol. 2004, 172:2126-2136.
81. Yang M., Chen J., Su F., Yu B., Lin L., Liu Y., Huang J.D., Song E. Microvesicles secreted by macrophages shuttle invasion-potentiating microRNAs into breast cancer cells. Mol. Cancer 2011, 10:117.
82. Dai S., Wei D., Wu Z., Zhou X., Wei X., Huang H., Li G. Phase I clinical trial of autologous ascites-derived exosomes combined with GM-CSF for colorectal cancer. Mol. Ther. 2008, 16:782-790.
83. Escudier B., Dorval T., Chaput N., Andre F., Caby M.P., Novault S., Flament C., Leboulaire C., Borg C., Amigorena S., Boccaccio C., Bonnerot C., Dhellin O., Movassagh M., Piperno S., Robert C., Serra V., Valente N., Le Pecq J.B., Spatz A., Lantz O., Tursz T., Angevin E., Zitvogel L. Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial. J. Transl. Med. 2005, 3:10.
84. Morse M.A., Garst J., Osada T., Khan S., Hobeika A., Clay T.M., Valente N., Shreeniwas R., Sutton M.A., Delcayre A., Hsu D.H., Le Pecq J.B., Lyerly H.K. A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J. Transl. Med. 2005, 3:9.
85. Tan A., De La Pena H., Seifalian A.M. The application of exosomes as a nanoscale cancer vaccine. Int. J. Nanomedicine 2010, 5:889-900.
86. Bhatnagar S., Shinagawa K., Castellino F.J., Schorey J.S. Exosomes released from macrophages infected with intracellular pathogens stimulate a proinflammatory response in vitro and in vivo. Blood 2007, 110:3234-3244.
87. Singh P.P., LeMaire C., Tan J.C., Zeng E., Schorey J.S. Exosomes released from M. tuberculosis infected cells can suppress IFN-gamma mediated activation of naive macrophages. PLoS One 2011, 6:e18564.
88. Buzas E.I., Gyorgy B., Nagy G., Falus A., Gay S. Emerging role of extracellular vesicles in inflammatory diseases. Nat. Rev. Rheumatol. 2014, 10:356-364.
89. Skriner K., Adolph K., Jungblut P.R., Burmester G.R. Association of citrullinated proteins with synovial exosomes. Arthritis Rheum. 2006, 54:3809-3814.
90. Zhang H.G., Liu C., Su K., Yu S., Zhang L., Zhang S., Wang J., Cao X., Grizzle W., Kimberly R.P. A membrane form of TNF-alpha presented by exosomes delays T cell activation-induced cell death. J. Immunol. 2006, 176:7385-7393.
91. Rahman M.J., Regn D., Bashratyan R., Dai Y.D. Exosomes released by islet-derived mesenchymal stem cells trigger autoimmune responses in NOD mice. Diabetes 2014, 63:1008-1020.
92. Lehmann S.M., Kruger C., Park B., Derkow K., Rosenberger K., Baumgart J., Trimbuch T., Eom G., Hinz M., Kaul D., Habbel P., Kalin R., Franzoni E., Rybak A., Nguyen D., Veh R., Ninnemann O., Peters O., Nitsch R., Heppner F.L., Golenbock D., Schott E., Ploegh H.L., Wulczyn F.G., Lehnardt S. An unconventional role for miRNA: let-7 activates Toll-like receptor 7 and causes neurodegeneration. Nat. Neurosci. 2012, 15:827-835.
93. Liu G., Abraham E. MicroRNAs in immune response and macrophage polarization. Arterioscler. Thromb. Vasc. Biol. 2013, 33:170-177.
94. McDonald M.K., Tian Y., Qureshi R.A., Gormley M., Ertel A., Gao R., Aradillas Lopez E., Alexander G.M., Sacan A., Fortina P., Ajit S.K. Functional significance of macrophage-derived exosomes in inflammation and pain. Pain 2014, 155:1527-1539.
95. Gupta A., Pulliam L. Exosomes as mediators of neuroinflammation. J. Neuroinflammation 2014, 11:68.
96. Kulshreshtha A., Ahmad T., Agrawal A., Ghosh B. Proinflammatory role of epithelial cell-derived exosomes in allergic airway inflammation. J. Allergy Clin. Immunol. 2013, 131:1194-1203. (1203 e1191-1114).
97. Sun D., Zhuang X., Xiang X., Liu Y., Zhang S., Liu C., Barnes S., Grizzle W., Miller D., Zhang H.G. A novel nanoparticle drug delivery system: the anti-inflammatory activity of curcumin is enhanced when encapsulated in exosomes. Mol. Ther. 2010, 18:1606-1614.
98. Kim S.H., Bianco N., Menon R., Lechman E.R., Shufesky W.J., Morelli A.E., Robbins P.D. Exosomes derived from genetically modified DC expressing FasL are anti-inflammatory and immunosuppressive. Mol. Ther. 2006, 13:289-300.
99. Admyre C., Johansson S.M., Qazi K.R., Filen J.J., Lahesmaa R., Norman M., Neve E.P., Scheynius A., Gabrielsson S. Exosomes with immune modulatory features are present in human breast milk. J. Immunol. 2007, 179:1969-1978.
100. Ostman S., Taube M., Telemo E. Tolerosome-induced oral tolerance is MHC dependent. Immunology 2005, 116:464-476.
101. Neurath M.F. Cytokines in inflammatory bowel disease. Nat. Rev. Immunol. 2014, 14:329-342.
102. Cai Z., Zhang W., Yang F., Yu L., Yu Z., Pan J., Wang L., Cao X., Wang J. Immunosuppressive exosomes from TGF-beta1 gene-modified dendritic cells attenuate Th17-mediated inflammatory autoimmune disease by inducing regulatory T cells. Cell Res. 2012, 22:607-610.
103. Yu L., Yang F., Jiang L., Chen Y., Wang K., Xu F., Wei Y., Cao X., Wang J., Cai Z. Exosomes with membrane-associated TGF-beta1 from gene-modified dendritic cells inhibit murine EAE independently of MHC restriction. Eur. J. Immunol. 2013, 43:2461-2472.
104. Teng H., Hu M., Yuan L.X., Liu Y., Guo X., Zhang W.J., Jia R.Z. Suppression of inflammation by tumor-derived exosomes: a kind of natural liposome packaged with multifunctional proteins. J. Liposome Res. 2012, 22:346-352.
105. Pusic A.D., Pusic K.M., Clayton B.L., Kraig R.P. IFNgamma-stimulated dendritic cell exosomes as a potential therapeutic for remyelination. J. Neuroimmunol. 2014, 266:12-23.
106. Viaud S., Ploix S., Lapierre V., Thery C., Commere P.H., Tramalloni D., Gorrichon K., Virault-Rocroy P., Tursz T., Lantz O., Zitvogel L., Chaput N. Updated technology to produce highly immunogenic dendritic cell-derived exosomes of clinical grade: a critical role of interferon-gamma. J. Immunother. 2011, 34:65-75.
107. Schory J.S., Bhatnaga S. Exosome Function: From tumor immunology to pathogen biology. Traffic 2008, 9:871-881.